vs

Side-by-side financial comparison of Granite Point Mortgage Trust Inc. (GPMT) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

Granite Point Mortgage Trust Inc. is the larger business by last-quarter revenue ($29.1M vs $19.6M, roughly 1.5× STANDARD BIOTOOLS INC.). Granite Point Mortgage Trust Inc. runs the higher net margin — -81.9% vs -177.4%, a 95.5% gap on every dollar of revenue. On growth, STANDARD BIOTOOLS INC. posted the faster year-over-year revenue change (-11.5% vs -24.9%). Over the past eight quarters, Granite Point Mortgage Trust Inc.'s revenue compounded faster (52.3% CAGR vs -12.2%).

Granite Point Mortgage Trust Inc. is a U.S.-based real estate finance company that primarily originates, manages and invests in senior secured commercial real estate debt instruments. Its core portfolio covers loans backed by multifamily, office, industrial, retail and other commercial property types across key U.S. regional markets, serving institutional and commercial real estate operator clients.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

GPMT vs LAB — Head-to-Head

Bigger by revenue
GPMT
GPMT
1.5× larger
GPMT
$29.1M
$19.6M
LAB
Growing faster (revenue YoY)
LAB
LAB
+13.5% gap
LAB
-11.5%
-24.9%
GPMT
Higher net margin
GPMT
GPMT
95.5% more per $
GPMT
-81.9%
-177.4%
LAB
Faster 2-yr revenue CAGR
GPMT
GPMT
Annualised
GPMT
52.3%
-12.2%
LAB

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
GPMT
GPMT
LAB
LAB
Revenue
$29.1M
$19.6M
Net Profit
$-23.8M
$-34.7M
Gross Margin
48.5%
Operating Margin
-81.9%
-168.5%
Net Margin
-81.9%
-177.4%
Revenue YoY
-24.9%
-11.5%
Net Profit YoY
38.7%
-28.8%
EPS (diluted)
$-0.58
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GPMT
GPMT
LAB
LAB
Q4 25
$29.1M
Q3 25
$33.7M
$19.6M
Q2 25
$33.8M
$21.8M
Q1 25
$35.1M
$40.8M
Q4 24
$38.7M
Q3 24
$44.3M
$22.1M
Q2 24
$48.5M
$22.5M
Q1 24
$12.5M
$45.5M
Net Profit
GPMT
GPMT
LAB
LAB
Q4 25
$-23.8M
Q3 25
$3.0M
$-34.7M
Q2 25
$-13.4M
$-33.5M
Q1 25
$-7.0M
$-26.0M
Q4 24
$-38.8M
Q3 24
$-31.0M
$-26.9M
Q2 24
$-63.1M
$-45.7M
Q1 24
$-74.1M
$-32.2M
Gross Margin
GPMT
GPMT
LAB
LAB
Q4 25
Q3 25
48.5%
Q2 25
48.8%
Q1 25
48.4%
Q4 24
Q3 24
54.9%
Q2 24
46.1%
Q1 24
53.1%
Operating Margin
GPMT
GPMT
LAB
LAB
Q4 25
-81.9%
Q3 25
9.2%
-168.5%
Q2 25
-39.5%
-118.1%
Q1 25
-19.8%
-80.8%
Q4 24
-100.3%
Q3 24
-70.0%
-120.9%
Q2 24
-130.1%
-134.5%
Q1 24
-591.9%
-132.2%
Net Margin
GPMT
GPMT
LAB
LAB
Q4 25
-81.9%
Q3 25
9.0%
-177.4%
Q2 25
-39.5%
-153.7%
Q1 25
-20.0%
-63.8%
Q4 24
-100.3%
Q3 24
-70.0%
-122.0%
Q2 24
-130.1%
-203.3%
Q1 24
-591.9%
-70.6%
EPS (diluted)
GPMT
GPMT
LAB
LAB
Q4 25
$-0.58
Q3 25
$-0.01
$-0.09
Q2 25
$-0.35
$-0.09
Q1 25
$-0.22
$-0.07
Q4 24
$-0.86
Q3 24
$-0.69
$-0.07
Q2 24
$-1.31
$-0.12
Q1 24
$-1.53
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GPMT
GPMT
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$66.0M
$129.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$552.7M
$399.7M
Total Assets
$1.8B
$539.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GPMT
GPMT
LAB
LAB
Q4 25
$66.0M
Q3 25
$62.7M
$129.4M
Q2 25
$85.1M
$158.6M
Q1 25
$85.7M
$150.9M
Q4 24
$87.8M
Q3 24
$113.5M
$210.6M
Q2 24
$85.9M
$269.8M
Q1 24
$155.2M
$287.1M
Total Debt
GPMT
GPMT
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Stockholders' Equity
GPMT
GPMT
LAB
LAB
Q4 25
$552.7M
Q3 25
$582.0M
$399.7M
Q2 25
$584.2M
$424.5M
Q1 25
$604.7M
$454.6M
Q4 24
$619.1M
Q3 24
$667.8M
$489.3M
Q2 24
$704.6M
$510.3M
Q1 24
$774.1M
$577.3M
Total Assets
GPMT
GPMT
LAB
LAB
Q4 25
$1.8B
Q3 25
$1.8B
$539.6M
Q2 25
$1.9B
$557.0M
Q1 25
$2.0B
$579.6M
Q4 24
$2.1B
Q3 24
$2.3B
$681.5M
Q2 24
$2.5B
$708.7M
Q1 24
$2.7B
$777.7M
Debt / Equity
GPMT
GPMT
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GPMT
GPMT
LAB
LAB
Operating Cash FlowLast quarter
$2.7M
$-22.2M
Free Cash FlowOCF − Capex
$-23.1M
FCF MarginFCF / Revenue
-118.1%
Capex IntensityCapex / Revenue
4.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GPMT
GPMT
LAB
LAB
Q4 25
$2.7M
Q3 25
$4.5M
$-22.2M
Q2 25
$736.0K
$-20.7M
Q1 25
$-5.7M
$-30.3M
Q4 24
$8.8M
Q3 24
$6.1M
$-27.9M
Q2 24
$987.0K
$-39.0M
Q1 24
$1.7M
$-62.5M
Free Cash Flow
GPMT
GPMT
LAB
LAB
Q4 25
Q3 25
$-23.1M
Q2 25
$-22.6M
Q1 25
$-35.3M
Q4 24
Q3 24
$-30.1M
Q2 24
$-41.0M
Q1 24
$-63.3M
FCF Margin
GPMT
GPMT
LAB
LAB
Q4 25
Q3 25
-118.1%
Q2 25
-103.6%
Q1 25
-86.6%
Q4 24
Q3 24
-136.4%
Q2 24
-182.2%
Q1 24
-138.9%
Capex Intensity
GPMT
GPMT
LAB
LAB
Q4 25
Q3 25
4.5%
Q2 25
8.7%
Q1 25
12.4%
Q4 24
Q3 24
10.2%
Q2 24
8.6%
Q1 24
1.7%
Cash Conversion
GPMT
GPMT
LAB
LAB
Q4 25
Q3 25
1.49×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GPMT
GPMT

Segment breakdown not available.

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons